

Clinical Policy: Capmatinib (Tabrecta)

Reference Number: CP.PHAR.494

Effective Date: 09.01.20

Last Review Date: 08.25

Line of Business: Commercial, HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Capmatinib (Tabrecta[®]) is a kinase inhibitor that targets mesenchymal-epithelial transition (MET).

FDA Approved Indication(s)

Tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Tabrecta is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Non-Small Cell Lung Cancer** (must meet all):

1. Diagnosis of recurrent, advanced, or metastatic NSCLC;
2. Prescribed by or in consultation with an oncologist;
3. Age $\geq$ 18 years;
4. Disease is positive for a mutation causing MET exon 14 skipping (*see Appendix D*);
5. Member meets one of the following (a, b, or c):
 - a. Disease is epidermal growth factor receptor (EGFR) wild-type and anaplastic lymphoma kinase (ALK) negative;
 - b. Used as a single-agent for brain metastases;
 - c. If EGFR mutant with high-level MET amplifications, Tabrecta can be administered with continuation of Tagrisso[®];
6. For Tabrecta requests, member must use generic capmatinib, if available, unless contraindicated or clinically significant adverse effects are experienced;
7. Request meets one of the following (a or b):*
 - a. Dose does not exceed both of the following (i and ii):
 - i. 800 mg per day;
 - ii. 4 tablets per day;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration:

Medicaid/HIM – 6 months

Commercial – 12 months or duration of request, whichever is less

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Non-Small Cell Lung Cancer (must meet all):

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Tabrecta for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):*
 - a. New dose does not exceed both of the following (i and ii):
 - i. 800 mg per day;
 - ii. 4 tablets per day;
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration:

Medicaid/HIM – 12 months

Commercial – 12 months or duration of request, whichever is less

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business:

- CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
- b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents;
- B. Positive MET amplification WITHOUT an Exon 14 skipping mutation.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

MET: mesenchymal-epithelial transition

NSCLC: non-small cell lung cancer

EGFR: epidermal growth factor receptor

ALK: anaplastic lymphoma kinase

Appendix B: Therapeutic Alternatives

Not applicable

Appendix C: Contraindications/Boxed Warnings

None reported

Appendix D: General Information

- Mutation causing MET exon 14 skipping
 - The test is interpreted by the pathologist that signs the report.
 - The ONLY test that should be POSITIVE is the presence of an Exon 14 Skipping Mutation for the MET gene.
 - The following results should be considered NEGATIVE:
 - Presence of MET amplification WITHOUT the presence of an Exon 14 skipping mutation of the MET gene.
 - Presence of any other genomic aberration (mutation, deletion, rearrangement) of the MET gene.
 - There exists a potential for abuse/misuse of the drug would be if the patient's tumor had a MET amplification ONLY. The drug was tested AND found to be ineffective in patients whose tumors were positive for the MET amplification WITHOUT an Exon 14 Skipping Mutation. Thus, the drug should NOT be

approved for a positive MET amplification WITHOUT an Exon 14 skipping mutation.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
NSCLC	400 mg PO BID	800 mg/day

VI. Product Availability

Tablets: 150 mg, 200 mg

VII. References

1. Tabrecta Prescribing Information. East Hanover, NJ; Novartis Pharmaceuticals Corporation: March 2024. Available at: www.us.tabrecta.com. Accessed April 10, 2025.
2. Capmatinib. In: National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed May 25, 2025.
3. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer. Version 4.2025. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed May 25, 2025.
4. National Comprehensive Cancer Network. Central Nervous System Cancers. Version 5.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed May 25, 2025.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
3Q 2021 annual review: no significant changes; added in Section III: Positive MET amplification WITHOUT an Exon 14 skipping mutation; added legacy WellCare line of business with a separate approval duration (WCG.CP.PHAR.494 to be retired); updated reference for HIM off-label use to HIM.PA.154 (replaces HIM.PHAR.21); references reviewed and updated.	04.02.21	08.21
Revised approval duration for Commercial line of business from length of benefit to 12 months or duration of request, whichever is less	01.20.22	05.22
3Q 2022 annual review: no significant changes; added option for recurrent disease per NCCN; references reviewed and updated.	05.03.22	08.22
RT4: NSCLC indication converted to full FDA approval, added standard oral oncology generic redirection language; Legacy Wellcare approval duration consolidated to standard Medicaid approval duration of 6/12 months. Template changes applied to other diagnoses/indications.	08.24.22	
3Q 2023 annual review: no significant changes; references reviewed and updated.	05.08.23	08.23
3Q 2024 annual review: for initial criteria: added option for “if EGFR mutant with high-level MET amplifications, Tabrecta is	05.13.24	08.24

Reviews, Revisions, and Approvals	Date	P&T Approval Date
used with Tagrisso” per NCCN; removed “member does not have symptomatic CNS metastases” as Tabrecta may be used in CNS brain metastases per NCCN; references reviewed and updated.		
3Q 2025 annual review: for initial criteria: added option for “used as a single-agent for brain metastases” per NCCN; updated EGFR mutant with high-level MET amplifications criteria from “Tabrecta is used with Tagrisso” to “Tabrecta can be administered with continuation of Tagrisso” per NCCN guideline; references reviewed and updated.	04.10.25	08.25

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to

recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2020 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.